title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
Results | Seven subjects dropped out during the study, resulting in a total of 21 subjects (FOS group, n = 10 [M: 5, F: 5); PL group, n = 11 [M: 5, F: 6]). Reasons for dropouts are noted in the participant flow diagram (Baseline participant characteristics.Data are mean (SD). Omega-3 Index = %EPA + %DHA in red blood cells | PMC9970203 | ||
Dietary intake | All dietary data, normalized by body mass (kg) for the macronutrients, are reported in Nutritional analysis.Amount of EPA and DHA does not include supplementationAbbreviations: FO, fish oil; PL, placebo; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid | PMC9970203 | ||
Volume load | ± | Total volume load over the 10 weeks was similar between conditions (FOS: 42,670 ± 18,925 kg, PL: 43,879 ± 22,765 kg, Weekly Volume Load for the a) Back Squat and b) Bench Press. Data are mean ± SD.*significantly different than week 1 for PL (Back Squat: | PMC9970203 | |
Strength testing | The 1RM strength data are shown in Individual Data Points of the Change in Relative a) 1RM Bench Press (1RM | PMC9970203 | ||
Discussion | muscle mass, RET, skeletal muscle adaptations | To our knowledge, this is the first study to investigate the effects of FOS compared to PL on skeletal muscle adaptations following a 10-week RET program in young adults, while using a membrane-centric hypothesis. We demonstrated that 3.85 g combined EPA and DHA daily for 10-weeks resulted in significantly greater RET-... | PMC9970203 | |
Conclusion | RET, skeletal muscle adaptations | In summary, our data confirms, once again, that RET is key for beneficial skeletal muscle adaptations and body recomposition in young healthy men and women. The addition of fish oil supplementation (4 g∙d | PMC9970203 | |
Acknowledgments | The authors would like to thank the participants and training staff for their hard work and dedication to this study. The results of the present study do not constitute product endorsement by the authors or the ISSN. The views and information presented are those of the authors and do not represent the official position... | PMC9970203 | ||
Disclosure statement | No potential conflict of interest was reported by the author(s). | PMC9970203 | ||
Author contributions | Study Design: JLH, LKF, JSF, NDB, AJK, ST; Funding Acquisition: JLH, LKF, AG; Data Collection: JLH, LKF, SBM, DRH, and LCS; Data Analysis: JLH and ST; Manuscript Writing: JLH, SBM, LKF, DRH, NDB, AJK, JSF; Final Manuscript Review and Approval: JLH, SBM, DRH, LKF, JSF, NDB, AJK, ST, LCS, and AG. | PMC9970203 | ||
References | PMC9970203 | |||
Background | SECONDARY CANCER, BREAST CANCER | Contributed equally.Contributed equallyTamoxifen is an established treatment for breast cancer, but its long-term effects on survival and on secondary cancers are not fully evaluated. | PMC10400913 | |
Material and methods | We studied 30 years outcome of 4124 postmenopausal patients who were randomized to receive (totally) two or five years of adjuvant tamoxifen. | PMC10400913 | ||
Results | lung cancer, endometrial cancer, breast cancer | ENDOMETRIAL CANCER, BREAST CANCER, CONTRALATERAL BREAST CANCER, DISEASE, LUNG CANCER | After 5 years of follow-up, when tamoxifen treatment was finished in both groups, until 15 years of follow-up, overall mortality (HR 0.80, 95% CI 0.72–0.90, p < 0.001), breast cancer mortality for all patients (HR 0.80, 95% CI 0.68–0.94, p = 0.006) and breast cancer mortality for patients with estrogen receptor positiv... | PMC10400913 |
Conclusion | lung cancer, endometrial cancer, breast cancer | LUNG CANCER, CONTRALATERAL BREAST CANCER, ENDOMETRIAL CANCER, BREAST CANCER | Three more years of tamoxifen therapy reduced the risk of breast cancer mortality. The difference was established during the first 15 years after randomization. Moreover, the incidence of contralateral breast cancer gradually decreased for 30 years. The incidence of lung cancer was reduced in the five-year group. In co... | PMC10400913 |
Introduction | lung cancer, endometrial cancer, breast cancer | RECURRENCES, ENDOMETRIAL CANCER, RECURRENCE, ESTROGEN RECEPTOR POSITIVE BREAST CANCER, BREAST CANCER, CONTRALATERAL BREAST CANCER, LUNG CANCER | Tamoxifen is an effective adjuvant treatment for early breast cancer reducing recurrence and mortality rates [As first demonstrated by Fornander and coworkers, tamoxifen increased the risk of endometrial cancer [Estrogen receptor positive breast cancer is associated with late recurrences and prolonged follow-up from br... | PMC10400913 |
Materials and methods | Breast Cancer, tumors, breast cancer | BREAST CANCER, TUMORS, INVASIVE BREAST CANCER, BREAST CANCER | The trial was planned and organized by the Swedish Breast Cancer Group and involved five regional breast cancer centers and was approved by their Ethics Committees. Study characteristics by trial center are shown in Study characteristics by trial center.During the period 1983–1992 a total of 4610 postmenopausal women y... | PMC10400913 |
Statistical analyses | death | REGRESSION, EVENTS, EVENT | Time for follow-up was defined as the time from randomization until the first event, death, or last observation (December 31, 2019). Median time for follow up was 30.2 years for living patients and 17.4 years for all patients. We examined crude cumulative incidence rates which is failure probabilities for a particular ... | PMC10400913 |
Results | PMC10400913 | |||
Contralateral breast cancer | tamoxifen.13 | CONTRALATERAL BREAST CANCER, EVENTS | The incidence of contralateral breast cancer was reduced in the five-year group, HR 0.75 (95% CI 0.59–0.95, p = 0.029) as illustrated in Incidence of contralateral breast cancer. Events after 2 versus 5 years of tamoxifen treatment.CI = confidence interval; HR = hazard ratio; SHR = subhazard ratio; TAM = tamoxifen.13 p... | PMC10400913 |
Endometrial cancer | endometrial cancer | CONTRALATERAL BREAST CANCER, ENDOMETRIAL CANCER, EVENTS | In the five-year group, the incidence of endometrial cancer was increased compared with the two-year group, HR 1.65 (95% CI 1.12–2.42, p = 0.010), Incidence of endometrial cancer. Events after 2 versus 5 years of tamoxifen treatment.CI = confidence interval; HR = hazard ratio; SHR = subhazard ratio; TAM = tamoxifen.22 ... | PMC10400913 |
Lung cancer | lung cancer, primary lung cancer | LUNG CANCER, CONTRALATERAL BREAST CANCER, EVENTS | In agreement with our previous report from this trialIncidence of primary lung cancer for patients randomized to two versus five years of tamoxifen.Incidence of lung cancer. Events after 2 versus 5 years of tamoxifen treatment. CI = confidence interval; HR = hazard ratio; SHR = subhazard ratio; TAM = tamoxifen.Before t... | PMC10400913 |
Discussion | endometrial cancer, breast cancer death, breast cancer, reduction of breast cancer, endometrial cancers, lung cancer, lung cancers, tumors | ENDOMETRIAL CANCER, RECURRENCE, BREAST CANCER, CONTRALATERAL BREAST CANCER, DISEASE, LUNG CANCER, LUNG CANCERS, EVENTS, TUMORS, METASTASES | In the present study with extended follow-up data, overall mortality, cumulative breast cancer mortality, incidence of contralateral breast cancer and incidence of lung cancer were delayed in the five year-group as compared to the two year-group. It is well known that the effect of tamoxifen remains beyond the duration... | PMC10400913 |
Funding | ALF, Cancer | CANCER | The study was supported by grants without numbers from the King Gustaf the Vth Jubilee Clinic Cancer Foundations in Gothenburg and from the Swedish governmental grants to scientists working in health care (ALF), the | PMC10400913 |
Declaration of interest statement | The authors have declared no conflicts of interest. | PMC10400913 | ||
Ethical approval | The present study of long-term effects of tamoxifen treatment has been carried out with the approval of the Regional Ethical Review Board in Linköping Sweden (Dnr 2011/317-31). | PMC10400913 | ||
Authors’ contributions | RECRUITMENT | A.N. wrote most of the manuscript, H.F. performed statistical analyses and prepared figures and tables in close collaboration with O.S., B.N. and A.W. planned the clinical trial with B.N. serving as PI. J.R. kept the database, T.F., T.H., H.L., NO.B. and P.M. were responsible for patient recruitment at their trial cent... | PMC10400913 | |
References | PMC10400913 | |||
Abbreviations |
confidence intervalestrogen receptorestrogen receptor positivehazard ratiosubhazard ratiotamoxifen | PMC10400913 | ||
Purpose: | HIV (PWH | To test the efficacy of two interventions to reduce alcohol use and increase viral suppression compared to a control in persons with HIV (PWH). | PMC10437504 | |
Methods: | NDD | DISORDERS | In a three-arm (1:1:1) randomized controlled trial (N = 269), we compared in-person counselling (45–70 minutes, two sessions over three months) with interim monthly booster phone calls (live call arm) or twice-weekly automated booster sessions (technology arm) to a brief advice control arm. We enrolled PWH self-reporti... | PMC10437504 |
Results: | reductions in mean NDDs, NDDs, viral suppression | At baseline, mean 21-day NDDs were 9.4 (95 % CI: 9.1–9.8), mean PEth was 407.8 ng/mL (95 % CI: 340.7–474.8), and 89.2 % were virally suppressed. At follow-up, there were significant reductions in mean NDDs for the live call versus control arm (3.5, 95 % CI:2.1–4.9, p < 0.001) and for the technology versus control arm (... | PMC10437504 | |
Conclusion: | NDD | Intervention effects were found on self-reported NDD but not PEth or viral suppression, suggesting no treatment effect.( | PMC10437504 | |
Introduction | PWH, HIV viral suppression | Alcohol consumption is a critical driver of poor HIV outcomes,especially in sub-Saharan Africa (SSA), where both are extremely common (The vast majority of PWH live in low-income settings, thus low-cost alcohol interventions, such as brief counselling-based interventions, are needed. A meta-analysis of alcohol counsell... | PMC10437504 | |
Methods | PMC10437504 | |||
Design | This was a 3-arm parallel design RCT with a 1:1:1 allocation ratio. | PMC10437504 | ||
Setting | ISS | SYNDROME, IMMUNE SUPPRESSION | The study took place in the semi-urban setting of Mbarara, Uganda. Participants were recruited from the Immune Suppression Syndrome (ISS) Clinic of the Mbarara Regional Referral Hospital (MRRH), an HIV clinic with over 11,000 active patients. | PMC10437504 |
Ethical approval | All study procedures were approved by the institutional review boards of the University of California, San Francisco, the Mbarara University of Science and Technology, and the Uganda National Council on Science and Technology. The study was registered at | PMC10437504 | ||
Inclusion criteria | DISORDERS | Inclusion criteria were being infected with HIV, 18 years and older, Alcohol Use Disorders Identification Test – Consumption (AUDIT-C, modified to cover the prior 3 months) positive (≥3 for women, ≥4 for men); having daily access to a working cell phone (confirmed by study staff); being prescribed antiretroviral therap... | PMC10437504 | |
Recruitment | We screened clinic patients who had reported any alcohol use via the AUDIT in their intake clinic visits or by clinic staff knowledge. All participants gave written informed consent to participate in the study in either English or Runyankole. | PMC10437504 | ||
Randomization and masking | Following baseline questionnaires and blood draw, we randomized participants to: (1) in-person brief workbook-based alcohol counseling at two regularly-scheduled quarterly clinic visits plus interim boosters delivered every 3 weeks by phone (live call arm); (2) in-person brief workbook-based alcohol counseling at two r... | PMC10437504 | ||
Interventions | The in-person one-on-one counseling sessions, administered by a lay health-counselor in both intervention arms, were conducted in a private room at the clinic using an illustrated workbook. Before the trial, we adapted the workbook from a prior study (Booster sessions, tailored to participants’ drinking agreements and ... | PMC10437504 | ||
Fidelity | We audio-recorded the in-person counseling sessions and the Ugandan study coordinator reviewed 15 % of them for fidelity (n = 37), using a 17-item check-list of intervention components adapted to the current trial ( | PMC10437504 | ||
Adaptations for COVID-19 | MAY | On March 30, 2020, the Ugandan government issued restrictions on movement that lasted until May 22, 2020. During that time, we ceased in-person study visits. At the start of the restrictions, 31 persons were enrolled and had completed session one only. To avoid in-person contact, we extended delivery of booster session... | PMC10437504 | |
Assessments | We conducted a structured interviewer-administered questionnaire at baseline, six, and nine months. The baseline questionnaire included demographics and literacy ( | PMC10437504 | ||
Laboratory testing | We conducted venous blood draws at each study visit. We prepared dried blood spots (DBS) by pipetting 5 μL spots onto Whatman 903 cards. DBS cards were stored at −80 C and shipped in batches to a commercial laboratory for PEth quantification (16:0/18:1 analog), with limit of quantification (LOQ) of 8 ng/mL ( | PMC10437504 | ||
Primary outcomes | NDD, viral suppression | The primary outcomes were number of days drinking (NDD) alcohol in the prior 21 (calculated from the 30-day TLFB) and PEth at the six- and nine-month study visits, together, and viral suppression (<40 copies/mL) at nine months. We chose NDD to be consistent with a similar intervention ( | PMC10437504 | |
Secondary outcomes | Additional outcomes were the number of heavy drinking days (>3 drinks per day for women and >4 drinks per day for men) in the prior 21 days, the AUDIT-C score (0–12), unhealthy alcohol consumption (AUDIT-C positive), PEth ≥ 50 ng/mL (consistent with unhealthy drinking) ( | PMC10437504 | ||
Statistical methods | PMC10437504 | |||
Primary outcomes | NDD | We calculated summary statistics (proportions, means, and 95 % confidence intervals [CIs]) at baseline and follow up, overall and by randomization arm. For the primary analyses, we used mixed effects modeling of the follow up time points, using Intention to Treat. The models included random effects for participants, an... | PMC10437504 | |
Secondary outcomes and post-hoc analyses | NDD, anemia | REGRESSION, SECONDARY, ANEMIA, SEVERE ANEMIA | We constructed additional models for the secondary outcomes, using the logit link for binary outcomes, negative binomial distribution for count outcomes, and linear models for continuous outcomes, controlling for sex and the baseline level of the outcome variable. Our mixed model for the composite AUDIT-C/PEth variable... | PMC10437504 |
Sample size | The a priori sample size calculation assumed 90 % follow-up retention and used a simplifying t-test for power calculations. We found that a sample size of 90 per study arm, chosen for logistical feasibility, would yield 80 % power to detect a difference in the number of drinking days in the prior 21 between two study a... | PMC10437504 | ||
Results | PMC10437504 | |||
Enrollment and retention | From September 19, 2019 through December 20, 2020, 994 persons were approached, 321 were eligible, and 270 were randomized (Two-thirds (65.4 %) of the participants were male and the mean age was 40.2 (95 % CI: 39.1–41.3)( | PMC10437504 | ||
Intervention adherence and satisfaction | All participants in the intervention arms completed the first in-person session, and 97.8 % of persons in the live counselling arm and 94.4 % of participants in the technology arm completed session 2 ( | PMC10437504 | ||
Primary outcomes | NDD, NDDs, anemia | ANEMIA | The unadjusted means for NDDs and PEth by study month are presented (We found no evidence of effect modification by sex, baseline alcohol use (above or below the median NDD, PEth, and AUDIT-C≥8), baseline social desirability score (above or below the median), and whether the study visit occurred before or after the COV... | PMC10437504 |
Secondary outcomes and exploratory analyses | SDS | SECONDARY | The results for secondary alcohol outcome measures were consistent with the main findings. We observed statistically significant decreases in both intervention arms compared to the control at follow up when measured by self-reported number of heavy drinking days, AUDIT-C score, and unhealthy alcohol use by AUDIT-C (SDS... | PMC10437504 |
Discussion | PWH, multiple co-morbidities | We compared two versions of a brief multi-session alcohol intervention targeted to PWH with unhealthy alcohol use adapted for the Ugandan context (We suspect that the self-reported decreases in alcohol use were at least in part due to social desirability, as SDS scores increased over the study period. In qualitative in... | PMC10437504 | |
Acknowledgements | The authors would like to acknowledge the hard work of the Extend Team study staff, especially the counsellors and research assistants. We also thank the study participants for their time and participation. We dedicate this manuscript to the fond memory of Dr. Richard Saitz. | PMC10437504 | ||
Role of funding source | This work is funded by National Institutes of Health, National Institute of Alcohol Abuse and Alcoholism, Grant #R01 AA024990 and #K24 AA022586.Conflict of interestDr. Hahn received consulting fees from Pear Therapeutics in 2022. | PMC10437504 | ||
Abbreviations: | PhosphatidylethanolPersons with HIV | PMC10437504 | ||
References | NDD | REGRESSION, SECONDARY | Consort diagram for randomized controlled trial of two brief alcohol interventions versus a control. Primary outcomes by study arm over study months. A) Mean self-reported number of drinking days (NDD), prior 21, with 95 % confidence intervals. B) Mean phosphatidylethanol (PEth) ng/mL with 95 % confidence intervals.Bas... | PMC10437504 |
Background | heart failure | HEART FAILURE | It is an important strategy for healthcare providers to support heart failure patients with comprehensive aspects of self-management. A practical alternative to a comprehensive and user-friendly self-management program for heart failure patients is needed. This study aimed to develop a mobile self-management app progra... | PMC9827017 |
Methods | heart failure | HEART FAILURE, HEART | We developed a mobile app, called Heart Failure-Smart Life. The app was to provide educational materials using a daily health check-up diary, Q & A, and 1:1 chat, considering individual users’ convenience. An experimental study was employed using a randomized controlled trial to evaluate the effects of the program in p... | PMC9827017 |
Results | HEART | After 3 months of intervention, significant differences between experimental and control groups were shown in the New York Heart Association functional class ( | PMC9827017 | |
Conclusions | heart failure | HEART FAILURE | This study provides evidence that the mobile app program may provide benefits to its users, specifically improvements of symptom and cardiac diastolic function in patients with heart failure. Healthcare providers can effectively and practically guide and support patients with heart failure using comprehensive and conve... | PMC9827017 |
Keywords | PMC9827017 | |||
Background | fatigue, dizziness, depression, heart failure, shortness of breath | HEART FAILURE, CHRONIC DISEASE | Along with the increase in the global aging population, the prevalence of heart failure has rapidly increased. A recent survey by the National Health and Nutrition Examination in the United States estimated the prevalence of heart failure to be 6.2 million, approximately 2.2% of the adult population, between 2013 and 2... | PMC9827017 |
Methods | PMC9827017 | |||
Study design | This study was a non-blinded, randomized controlled trial (RCT). Data were collected from July 2018 to June 2019. In both the experimental and control groups, data were collected at baseline and 3-month follow-up. | PMC9827017 | ||
Participants and recruitment | heart failure, cognitive disorders | HEART FAILURE | Participants were recruited from cardiovascular outpatient clinics at two large tertiary medical centers in Korea. One hundred patients were screened for eligibility with the following criteria. Patients were eligible to participate if they were: (1) diagnosed with heart failure by a cardiologist and regularly visiting... | PMC9827017 |
Intervention | heart failure, illness | HEART FAILURE, HEART | Based on the international guidelines for the management of heart failure [The content of the final draft was developed as a mobile app program, named “Heart Failure-Smart Life”, with the cooperation of app development specialists. For comprehensive self-management and efficient communication between heart failure pati... | PMC9827017 |
Study variables | depression, Depression | HEART FAILURE, HEART | We collected baseline demographic and clinical information, including age, gender, the existence of a partner, education level, economic status, duration of heart failure, number of hospital admissions, and comorbidities.Physiological factors were measured on a three-part form, which included: (1) anthropometric measur... | PMC9827017 |
Statistical analyses | depression | Data collected in this study were analyzed using SPSS version 23.0 (IBM Corporation, Armonk, NY, USA). It was analyzed by a two-sided test at a significance level of 0.05. The demographic and clinical characteristics of the participants were represented by frequency, mean, and standard deviation. The differences in gen... | PMC9827017 | |
Results | PMC9827017 | |||
Effects of Heart Failure-Smart Life mobile app program | depression | HEART | Of the 36 participants in the experimental group, 24 (66.7%) reported that they had participated in the mobile app program regularly (more than 5 days per week), including the participation in recording health check-up diary, 1:1 chat with the cardiac nurse, physical activity and exercise, dietary change, medication in... | PMC9827017 |
Discussion | depression, heart failure, chronic disease | HEART FAILURE, HEART, SECONDARY, CHRONIC DISEASE | This study developed a mobile app of the Heart Failure-Smart Life that is a comprehensive self-management program for patients with heart failure and evaluated the effects of the program through a RCT design. It demonstrated no changes in the primary outcomes of psychosocial (depression and QoL) and behavioral factors ... | PMC9827017 |
Conclusions | heart failure | HEART FAILURE, HEART | A mobile-based self-management app, the Heart Failure-Smart Life, implied improvements in the experimental group’s functional class and cardiac diastolic function. Mobile apps appear to benefit patients’ continuous self-management and health outcomes, healthcare providers’ consecutive monitoring, effective communicatio... | PMC9827017 |
Acknowledgements | None. | PMC9827017 | ||
Author contributions | JSP | Study conceptualization was performed by JAA. Data curation was performed by EYC, JSP and JAA. Formal analysis was performed by JAA and SA. Funding acquisition was performed by JAA. Supervision was performed by EYC, JSP and JAA. Writing was performed by JAA and DM. All authors reviewed the manuscript. All authors read ... | PMC9827017 | |
Funding | This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (NRF-2017R1C1B1007090 & NRF-2022R1F1A1075049). This funding source had no role in study design, data collection, data analysis, data interpretation, or writing of t... | PMC9827017 | ||
Availability of data and materials | The data that support the findings of this study are available from the corresponding author upon reasonable request and with permission of the medical centers where the authors collected the data retrospectively. | PMC9827017 | ||
Declarations | PMC9827017 | |||
Ethics approval and consent to participate | The study was conducted with the approval of the Institutional Review Boards (IRBs) of Ajou University Hospital and Gangnam Severance Hospital, Yonsei University (IRB No. AJIRB-MED-SUR-18–053 & 3–2018-0281). All participants completed written informed consent forms and were assured that their information would remain c... | PMC9827017 | ||
Consent for publication | Not applicable. | PMC9827017 | ||
Competing interests | All authors declare that they have no competing interests. | PMC9827017 | ||
References | PMC9827017 | |||
Background | sarcopenia, ICU-AW | SARCOPENIA | Intensive care unit-acquired weakness (ICU-AW) is a prevalent and severe issue among ICU patients. Resistance training and beta-hydroxy-beta-methylbutyrate (HMB) intervention have demonstrated the potential to enhance muscle function in patients with sarcopenia and in older adults. The purpose of this study was to dete... | PMC10724983 |
Methods | muscle mass | In this multicentre, four-arm, single-blind randomised control trial, a total of 112 adult patients with internal medical diagnoses admitted to the ICU were enrolled. These participants were then randomly assigned to one of four treatment groups: the resistance training group received protocol-based multilevel resistan... | PMC10724983 | |
Results | Resistance training and combination treatment groups exhibited significant increases in SPPB scores (3.848 and 2.832 points, respectively) compared to the control group and substantial improvements in 6WMD (99.768 and 88.577 m, respectively) (all with | PMC10724983 | ||
Conclusions | muscle mass | Resistance training with or without beta-hydroxy-beta-methylbutyrate during the entire hospitalisation intervention improves physical function and muscle strength in medical ICU patients, but muscle mass, quality of life, and 60-day mortality were unaffected. | PMC10724983 | |
Trial registration | ChiCTR2200057685 was registered on March 15th, 2022. | PMC10724983 | ||
Supplementary Information | The online version contains supplementary material available at 10.1186/s13054-023-04698-x. | PMC10724983 | ||
Keywords | PMC10724983 | |||
Background | skeletal muscle mass, critically ill, sarcopenia, ICU-AW, skeletal muscle wasting, cancer cachexia | CRITICALLY ILL, CRITICAL ILLNESS, SARCOPENIA, MUSCLE WASTING | Intensive care unit-acquired weakness (ICU-AW) is a frequent problem that induces skeletal muscle wasting while patients are suffering from a life-threatening condition [Emerging research indicates the significant influence of beta-hydroxy-beta-methylbutyrate (HMB) on skeletal muscle mass and physical function in a cli... | PMC10724983 |
Methods | PMC10724983 | |||
Study design | This four-arm, multicentre RCT was registered in the Clinical Trials Registry (ChiCTR2200057685) and approved by the Fujian Provincial Hospital Human Research Ethics Committee (K2021-04-004). All procedures were carried out in compliance with ethical norms for human experimentation as well as the Helsinki Declaration o... | PMC10724983 | ||
Participants and settings | This trial was conducted in 10 ICUs at five academic and tertiary comprehensive hospitals in Fujian province, China. Medical centre enrolment criteria are more than 15 beds in each ICU, and more than 500 ICU patients admitted to each ICU per year. We included adult patients who were admitted to the ICU with medical cri... | PMC10724983 | ||
Inclusion criteria for patients were as follows | (1) aged 18 to 80 years, (2) expected to stay in the ICU for more than 48 h, (3) could walk independently two weeks before transfer to ICU, (4) APACHE-II ≥ 8 points, (5) patients were awake and able to cooperate with five standardised questions ≥ 3 points [ | PMC10724983 | ||
Patients were excluded from the study if they met any of the following criteria | impaired consciousness, bleeding, arrhythmia, Guillain, Barré syndrome, long-term physical dysfunction, brain injury, cognitive dysfunction, VTE, venous thromboembolism | PULMONARY EMBOLISM, BLEEDING, MYOCARDIAL INFARCTION, ARRHYTHMIA, DEEP VEIN THROMBOSIS (DVT), RUPTURED THORACIC AORTIC ANEURYSM, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, MYASTHENIA GRAVIS, ASTHMA, SEVERE PULMONARY HYPERTENSION | (1) incapable of doing the early activity or rehabilitation exercises, such as being in the acute phase of myocardial infarction, having a ruptured thoracic aortic aneurysm, or obstructive hypertrophic cardiomyopathy, uncontrolled lethal arrhythmia, pulmonary embolism, acute phase of asthma, severe pulmonary hypertensi... | PMC10724983 |
Patients were withdrawn if they met any of the following criteria | death | COMPLICATIONS | (1) voluntary withdrawal from the study during the intervention; (2) acute complications, making the continuation of the intervention impossible, or necessitating termination of the intervention due to changes in condition, death, etc. | PMC10724983 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.